Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD

Longitudinal Natural History Protocol for PRKN- and PINK1-linked PD

Background:

Parkinson s disease is a neurologic disorder that affects movement. Its cause is unknown, and it usually begins later in life. Gene changes (PRKN and PINK1) can also cause rare types of Parkinson s disease that start at a young age. Researchers want to conduct a natural history study to learn more about how genes play a role in Parkinson s disease.

Objective:

To collect data and biological samples from people with different types of Parkinson s disease.

Eligibility:

People aged 18 to 80 years with either Parkinson s disease or PRKN- and PINK1-linked Parkinson s disease. Healthy volunteers are also needed.

Design:

Participants will have 6 clinic visits over 5 years. Each visit may take 1 to 3 days.

During each visit:

Participants will have a physical exam. The exam will be videotaped.

They will answer questions about their movement, thinking, mood, and sense of smell. The extent of any symptoms of Parkinson s disease will be evaluated: Participants movements may be assessed with a finger tapping test. They may be asked to scratch and sniff different scented strips to identify odors.

They will wear motion sensors on their arms, legs, chest, and back at the clinic. They will wear motion sensor devices on their wrists at home for 1 week.

Blood and urine samples will be collected.

Other tests are optional:

Magnetic resonance imaging (MRI) scan of the brain. Participants will lie on a table that slides into a tube.

Lumbar puncture (spinal tap). A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.

Muscle biopsy. A small sample of tissue will be taken from the leg.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

Study Description:

This is a longitudinal, observational study that aims to assess progression of clinical features, imaging, and biologic markers of PD in study participants with and without manifest PD who are bi-allelic or mono-allelic carriers of pathogenic variants in the recessively inherited genes PRKN and PINK1 that represent prototypes of mitochondrial- associated PD.

Objectives:

Primary Objective: To characterize the natural history of motor symptoms in PRKN- and PINK1-linked PD.

Secondary Objectives: To comprehensively characterize other clinical features of PRKN- and PINK1-linked PD over time

Tertiary Objectives:

  • To characterize structural brain changes over time
  • To identify molecular signatures that differ between PRKN and PINK1-associated PD, non-manifesting mutation carriers, wildtype PD, and healthy controls.
  • To generate a repository of longitudinal data and samples for future studies aimed at developing targeted therapies.
  • To characterize in-home assessment of movements
  • To evaluate for mitochondrial changes in the muscle

Endpoints:

Primary Endpoint: Annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

Secondary Endpoints:

  • Annual change in MDS-UPDRS parts I, II, IV
  • Annual change in Montreal Cognitive Assessment (MoCA)
  • Annual change in Timed up and go (TUG)
  • Annual change in 10-meter walk
  • Annual change in 360 degree turn
  • Annual change in Unified Dyskinesia Rating Scale (UDysRS)
  • Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
  • Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
  • Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
  • Annual change in Epworth Sleepiness Scale (ESS)
  • Annual change in Geriatric Depression Scale (GDS)
  • Annual change in State-Trait Anxiety Inventory (STAI)
  • Annual change in Scales for Outcomes in Parkinson s Disease - Autonomic Dysfunction (SCOPA AUT)
  • Annual change in 39-item Parkinson s Disease Questionnaire (PDQ-39)- quality of life measurement
  • Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
  • Annual change in Hoehn and Yahr scale assessment Tertiary endpoints:
  • Annual change of brain MRI measurement of overall brain, striatum and substantia nigra volumes
  • Annual change of brain MRI measurement of iron deposition
  • Annual change in studies from blood
  • Annual change in studies from CSF
  • Annual change in studies from urine
  • Annual change in Wearable Accelerometry data
  • Evidence of mitochondrial cytopathy on muscle biopsy

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

70

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Maryland
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • National Institutes of Health Clinical Center
        • Kontakt:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • Telefonnummer: TTY dial 711 800-411-1222
          • E-Mail: ccopr@nih.gov

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

There will be a total of up to 50 male or female participants 18- 80 years of age and older in 5 cohorts. Target number of completers for each cohort are listed below: - PD mito-biallelic (PD participants carrying two pathogenic variants in PRKN or PINK1): up to 15 - PD mito-monoallelic (PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1): up to 10 - PD idiopathic: up to 5 - Non-manifesting mito (participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD): up to 15 - Healthy controls: up to 5

Beschreibung

  • INCLUSION CRITERIA:

To be eligible to participate in this study, an individual must meet all of the following criteria:

All participants:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female between the ages of 18-80 years old
  • Ability of subject to understand and the willingness to sign an informed consent document
  • Ability of subject to travel to the NIH Clinical Center

Additional inclusion criteria for each cohort as below:

PD Mito Biallelic:

  • Established clinical diagnosis of Parkinson s disease
  • Two Pathogenic or likely pathogenic variants in PRKN or PINK1

PD Mito Monoallelic:

  • Established clinical diagnosis of Parkinson s disease
  • One Pathogenic or likely pathogenic variant in PRKN and/or PINK1

Idiopathic Parkinson s Disease (PD):

  • Established clinical diagnosis of Parkinson s disease
  • Etiology of PD is idiopathic/sporadic based on investigator determination

Non-manifesting mito:

  • One or two pathogenic or likely pathogenic variant in PRKN and/or PINK1
  • Lack of clinical diagnosis of Parkinson s disease
  • Lack of current or clinically significant neurological disorder (based on investigator determination)

Healthy Volunteer

-Lack of current or clinically significant neurological disorder (based on investigator determination)

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

All participants:

  • Symptomatic PD syndromes due to drugs (e.g., metoclopramide, flunarizine, neuroleptics), metabolic disorders (e.g., Wilson s disease hypothyroidism), encephalitis, brain lesion, atypical parkinsonism, other monogenic forms of PD (e.g., GBA1, LRRK2, SNCA, VPS35, CHCHD2, DJ1, ATP13A2) other genetic disorders that may cause parkinsonism (e.g., spinocerebellar ataxia, X-linked dystonia parkinsonism)
  • Pregnancy at time of study enrollment
  • Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment
  • Unwilling to allow samples or data to be shared with other researchers or institutions.
  • NIH staff or family members of study team members

Healthy Volunteer:

-Participants who become pregnant during the study will be withdrawn from further study procedures at the time pregnancy is identified.

Procedural Exclusions:

Subjects may still be enrolled if they cannot participate in certain procedures due to not meeting the inclusion requirements for that specific procedure. Subjects who meet exclusion criteria for procedures listed below may still undergo the procedure at a later time if the reason of exclusion is no longer present.

Brain MRI:

  • Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry)
  • Pregnancy

Accelerometer:

-Non ambulatory

Lumbar puncture procedure:

  • PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  • INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
  • History of a bleeding disorder
  • Use of anticoagulants or antiplatelets
  • Pregnancy
  • History of headache requiring blood patch after a previous LP

Needle muscle biopsy:

  • PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  • INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
  • History of a bleeding disorder
  • Use of anticoagulants or antiplatelets
  • Pregnancy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Healthy controls
Lack of current or clinically significant neurological disorder (based on investigator determination).
Non-manifesting mito
participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD
PD idiopathic
PD participants with idiopathic PD
PD mito - monoallelic
Monoallelic: PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1
PD mito - biallelic
Biallelic: PD participants carrying two pathogenic variants in PRKN or PINK1

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Estimation of progression of motor symptoms across cohorts
Zeitfenster: When final patient completes their last visit
Measured by annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
When final patient completes their last visit

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Annual change in MDS-UPDRS parts I, II, IV
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Montreal Cognitive Assessment (MoCA)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Timed up and go (TUG)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 10-meter walk
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 360 degree turn
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Unified Dyskinesia Rating Scale (UDysRS)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Epworth Sleepiness Scale (ESS)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Geriatric Depression Scale (GDS)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in State-Trait Anxiety Inventory (STAI)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA AUT)
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 39-item Parkinson's Disease Questionnaire (PDQ-39) - quality of life measurement
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Hoehn and Yahr scale assessment
Zeitfenster: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Debra J Ehrlich, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

30. Mai 2036

Studienabschluss (Geschätzt)

30. Mai 2036

Studienanmeldedaten

Zuerst eingereicht

28. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

28. Mai 2026

Zuerst gepostet (Tatsächlich)

29. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. Mai 2026

Zuletzt verifiziert

20. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • 10002619
  • 002619-N

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur PARKINSON DIS

Abonnieren